Johnson & Johnson (JNJ.US) announced that the EGFR/c-MET bispecific "avelumab" has been approved for a new indication in the country.
In February 2025, the drug was approved for the first time domestically for first-line treatment of EGFRex20ins-mutant NSCLC.
On August 8th, Johnson & Johnson (JNJ.US) announced that the EGFR/c-MET dual antibody "Amivantamab" has been approved for a new indication in China, in combination with Osimertinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with EGFR exon 19 deletions or L858R substitutions.
In February 2025, the drug was first approved in China for the first-line treatment of EGFRex20ins mutation NSCLC. In April 2025, the drug was approved for a new indication in China, in combination with chemotherapy for the treatment of patients with locally advanced or metastatic NSCLC after EGFR-TKI treatment. This is the third indication for Amivantamab approved in China.
Amivantamab was first granted accelerated approval for market in the United States in May 2021. To date, with a focus on non-small cell lung cancer, Amivantamab has been approved for four indications worldwide.
Related Articles

US Stock Market Move | Apple Inc. (AAPL.US) rose 2%, with reports that the iPhone 17 series will increase in price by $50.

US Stock Market Move | Most chip stocks are rising, Micron Technology, Inc. (MU.US) is up over 6%.

US Stock Market Move | HSAI.US (HSAI.US) rose more than 3% and showcased a new laser radar product at the Siasun Robot & Automation World Conference.
US Stock Market Move | Apple Inc. (AAPL.US) rose 2%, with reports that the iPhone 17 series will increase in price by $50.

US Stock Market Move | Most chip stocks are rising, Micron Technology, Inc. (MU.US) is up over 6%.

US Stock Market Move | HSAI.US (HSAI.US) rose more than 3% and showcased a new laser radar product at the Siasun Robot & Automation World Conference.

RECOMMEND

Seven Ministries Issue Comprehensive Roadmap for Brain-Computer Interface Industry Advances
08/08/2025

GPT-5 Makes a Late-Night Debut as Microsoft Leads Integration; Institutions Optimistic About Accelerated AI Programming Development
08/08/2025

Federal Reserve: U.S. Consumer Inflation Expectations Rose in July, Labor Market Sentiment Improved
08/08/2025